Zoetis has agreed to acquire Neogen Corporation’s animal genomics business for $160 million, a move that will add Neogen’s genetic testing platforms and data capabilities to Zoetis’s portfolio. The announced transaction coincided with a 1.55% decline in Zoetis shares on Monday.
The genomics unit being acquired operates five laboratories located in the United States, Brazil, Australia, China and the United Kingdom, and serves customers in more than 120 countries. The assets include technologies and data tools designed to predict animal health outcomes and enable more tailored care for individual animals.
Bank of America analysts observed that NEOG’s genomics segment had been underperforming in recent quarters, attributing the weakness to softer demand in Companion Animal testing as well as broader macro pressures such as inflation and weaker consumer spending. They also noted Neogen’s strategic shift toward larger production animals and that the company had previously signaled an intention to divest the genomics business to streamline its portfolio and prioritize higher-growth, more profitable Animal Safety markets. The analysts said the sale therefore was not unexpected.
Leerink analysts characterized the acquisition as a modest strategic enhancement rather than a major financial lever. In their view, the transaction strengthens Zoetis’s livestock operations and its genomics capabilities. "Although not a needle-mover, we think it makes strategic sense, modestly bolstering the company’s livestock focus and its genomics business," the Leerink team wrote. They added that the acquired assets derive a majority - approximately 55% - of revenue from cattle, which increases Zoetis’s exposure to what the analysts described as the best-performing livestock end market.
Leerink also highlighted that the genomics business had been through restructuring, including a move away from companion animal testing where demand had been weaker. The capabilities and data within the acquired business are intended to help farmers make more informed herd management decisions, which the analysts said can improve producer economics.
Taken together, the purchase expands Zoetis’s technical footprint in genetic testing and data-driven animal care, and shifts the company’s mix further toward livestock applications. Market reaction in the form of a share-price decline reflected investor assessment of the deal’s immediate financial significance, which analysts describe as limited.
Additional detail on integration plans, expected synergies, or timing for closing the transaction was not provided in the material used for this report.